Shape rescue in the midface phenotype in the Dp(16)1Yey/ <i>Ripply3</i>^<i>tm1b</i> compound mutant. by José Tomás Ahumada Saavedra (22290934)

“…In light blue, the structures with no significant changes. On the left, the histogram of every point distance evaluated (in this case, more than 1.238.684 points) and the surface differences with the color code for the increase-decrease dimensions (Red to green).…”

Differential miRNA target gene pathway enrichment bubble map. by Zhaowen Tan (12283502)

Subjects:

qRT-PCR results of differentially expressed miRNAs in rats’ myocardial tissue after training. by Zhaowen Tan (12283502)

Subjects:

Volcano plot and clustering of differentially expressed miRNAs. by Zhaowen Tan (12283502)

Subjects:

Summary of miRNAs sequencing data quality. by Zhaowen Tan (12283502)

Subjects:

Differential expression of miRNAs in SHR-SED group and BFRT group (all miRNAs). by Zhaowen Tan (12283502)

Subjects:

Histogram of the GO functional enrichment of differential miRNA target genes. by Zhaowen Tan (12283502)

Subjects:

The miRNA target genes. by Zhaowen Tan (12283502)

Subjects:

Changes in SHR body weight, hemodynamics and cardiac function before and after training. by Zhaowen Tan (12283502)

Subjects:

Table of miRNA comparisons with reference genomes. by Zhaowen Tan (12283502)

Subjects:

Statistical association (P < 0.10) between background factors and dog owners’ attitude (AT), subjective norms (SN) and perceived behavioral control (PBC) that were significantly as... by Fentahun Mengie (20862454)

Subjects:

Data Sheet 1_Eupalinolide A inhibits cancer progression and induces ferroptosis and apoptosis by targeting the AMPK/mTOR/SCD1 signalling in non-small cell lung cancer.docx by Yonghui Zhang (279832)

“…EA treatment (25 mg/kg) markedly inhibited tumour growth in vivo in a xenograft model; both tumour weight and tumour volume decreased by more than 60% without significantly affecting the body weight of tumour-bearing mice.…”

Figure 2 from mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of <i>PIK3CA</i>-Altered Tumors by Constance A. Sobsey (19373550)

“…Node size increases as the <i>P</i>-value decreases. <b>B,</b> Top 20 canonical pathways that are significantly differentially activated between clinical benefit (CB) and no clinical benefit (NCB) groups, based on assessment with Fisher’s exact test in Qiagen IPA. …”

Split structural models for belief. by Abigail A. Lee (19935335)

“…More conservative political views and higher income correlated with decreased hesitancy. No other latent variables or covariates had a significant effect on vaccine hesitancy. …”

Image 4_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…Background<p>Previous research has confirmed that integrating PD-1/PD-L1 inhibitors with chemotherapy (PC) represents a more effective strategy for treating advanced non-small-cell lung cancer (NSCLC). However, with the increasing number of phase 3 randomized controlled trials (RCTs) published in recent years, it is essential to re-evaluate the validity of this conclusion and to comprehensively assess the efficacy and safety across diverse patient subgroups.…”

Image 5_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…Background<p>Previous research has confirmed that integrating PD-1/PD-L1 inhibitors with chemotherapy (PC) represents a more effective strategy for treating advanced non-small-cell lung cancer (NSCLC). However, with the increasing number of phase 3 randomized controlled trials (RCTs) published in recent years, it is essential to re-evaluate the validity of this conclusion and to comprehensively assess the efficacy and safety across diverse patient subgroups.…”

Table 4_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…Background<p>Previous research has confirmed that integrating PD-1/PD-L1 inhibitors with chemotherapy (PC) represents a more effective strategy for treating advanced non-small-cell lung cancer (NSCLC). However, with the increasing number of phase 3 randomized controlled trials (RCTs) published in recent years, it is essential to re-evaluate the validity of this conclusion and to comprehensively assess the efficacy and safety across diverse patient subgroups.…”

Image 1_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…Background<p>Previous research has confirmed that integrating PD-1/PD-L1 inhibitors with chemotherapy (PC) represents a more effective strategy for treating advanced non-small-cell lung cancer (NSCLC). However, with the increasing number of phase 3 randomized controlled trials (RCTs) published in recent years, it is essential to re-evaluate the validity of this conclusion and to comprehensively assess the efficacy and safety across diverse patient subgroups.…”

Image 8_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…Background<p>Previous research has confirmed that integrating PD-1/PD-L1 inhibitors with chemotherapy (PC) represents a more effective strategy for treating advanced non-small-cell lung cancer (NSCLC). However, with the increasing number of phase 3 randomized controlled trials (RCTs) published in recent years, it is essential to re-evaluate the validity of this conclusion and to comprehensively assess the efficacy and safety across diverse patient subgroups.…”

Image 2_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…Background<p>Previous research has confirmed that integrating PD-1/PD-L1 inhibitors with chemotherapy (PC) represents a more effective strategy for treating advanced non-small-cell lung cancer (NSCLC). However, with the increasing number of phase 3 randomized controlled trials (RCTs) published in recent years, it is essential to re-evaluate the validity of this conclusion and to comprehensively assess the efficacy and safety across diverse patient subgroups.…”